Literature DB >> 27226537

Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding.

Line Barington1, Pia C Rummel1, Michael Lückmann2, Heidi Pihl1, Olav Larsen1, Viktorija Daugvilaite1, Anders H Johnsen3, Thomas M Frimurer4, Stefanie Karlshøj1, Mette M Rosenkilde5.   

Abstract

Chemokine receptors play important roles in the immune system and are linked to several human diseases. The initial contact of chemokines with their receptors depends on highly specified extracellular receptor features. Here we investigate the importance of conserved extracellular disulfide bridges and aromatic residues in extracellular loop 2 (ECL-2) for ligand binding and activation in the chemokine receptor CCR8. We used inositol 1,4,5-trisphosphate accumulation and radioligand binding experiments to determine the impact of receptor mutagenesis on both chemokine and small molecule agonist and antagonist binding and action in CCR8. We find that the seven-transmembrane (TM) receptor conserved disulfide bridge (7TM bridge) linking transmembrane helix III (TMIII) and ECL-2 is crucial for chemokine and small molecule action, whereas the chemokine receptor conserved disulfide bridge between the N terminus and TMVII is needed only for chemokines. Furthermore, we find that two distinct aromatic residues in ECL-2, Tyr(184) (Cys + 1) and Tyr(187) (Cys + 4), are crucial for binding of the CC chemokines CCL1 (agonist) and MC148 (antagonist), respectively, but not for small molecule binding. Finally, using in silico modeling, we predict an aromatic cluster of interaction partners for Tyr(187) in TMIV (Phe(171)) and TMV (Trp(194)). We show in vitro that these residues are crucial for the binding and action of MC148, thus supporting their participation in an aromatic cluster with Tyr(187) This aromatic cluster appears to be present in a large number of CC chemokine receptors and thereby could play a more general role to be exploited in future drug development targeting these receptors.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CCR8; G protein-coupled receptor (GPCR); chemokine receptor; metal ion-protein interaction; molecular pharmacology; mutagenesis in vitro; protein-protein interaction; receptor structure-function

Mesh:

Substances:

Year:  2016        PMID: 27226537      PMCID: PMC4965569          DOI: 10.1074/jbc.M115.706747

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3.

Authors:  Cédric Govaerts; Antoine Bondue; Jean-Yves Springael; Mireia Olivella; Xavier Deupi; Emmanuel Le Poul; Shoshana J Wodak; Marc Parmentier; Leonardo Pardo; Cédric Blanpain
Journal:  J Biol Chem       Date:  2002-10-30       Impact factor: 5.157

Review 2.  Chemokines and their receptors: drug targets in immunity and inflammation.

Authors:  Antonella Viola; Andrew D Luster
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Functional characterization of a series of mutant G protein alphaq subunits displaying promiscuous receptor coupling properties.

Authors:  E Kostenis; F Y Zeng; J Wess
Journal:  J Biol Chem       Date:  1998-07-10       Impact factor: 5.157

Review 4.  Interaction of chemokines with their receptors--from initial chemokine binding to receptor activating steps.

Authors:  Stefanie Thiele; Mette Marie Rosenkilde
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.

Authors:  P C Jensen; S Thiele; A Steen; A Elder; R Kolbeck; S Ghosh; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and -VI.

Authors:  Mette M Rosenkilde; Michael B Andersen; Rie Nygaard; Thomas M Frimurer; Thue W Schwartz
Journal:  Mol Pharmacol       Date:  2006-12-14       Impact factor: 4.436

Review 7.  Chemokine: receptor structure, interactions, and antagonism.

Authors:  Samantha J Allen; Susan E Crown; Tracy M Handel
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

8.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

9.  Identification of human CCR8 as a CCL18 receptor.

Authors:  Sabina A Islam; Morris F Ling; John Leung; Wayne G Shreffler; Andrew D Luster
Journal:  J Exp Med       Date:  2013-09-02       Impact factor: 14.307

10.  The probable arrangement of the helices in G protein-coupled receptors.

Authors:  J M Baldwin
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  3 in total

Review 1.  G Protein-Coupled Receptors in the Sweet Spot: Glycosylation and other Post-translational Modifications.

Authors:  Christoffer K Goth; Ulla E Petäjä-Repo; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-17

2.  Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.

Authors:  Astrid S Jørgensen; Olav Larsen; Edith Uetz-von Allmen; Michael Lückmann; Daniel F Legler; Thomas M Frimurer; Christopher T Veldkamp; Gertrud M Hjortø; Mette M Rosenkilde
Journal:  Front Immunol       Date:  2019-09-13       Impact factor: 7.561

3.  Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation.

Authors:  Suzan Fares; Katja Spiess; Emma T B Olesen; Jianmin Zuo; Sarah Jackson; Thomas N Kledal; Mark R Wills; Mette M Rosenkilde
Journal:  mBio       Date:  2019-01-15       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.